Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease.? We currently have 2 products commercialized and 3 drugs approved in the U.S.? Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.
        Drug
        Indication
        Topic
        ZL-2306 (Niraparib)
        Ovarian Cancer
        To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of platinum-sensitive recurrent ovarian cancer
        ZL-2306 (Niraparib)
        Ovarian Cancer
        To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of ovarian cancer patients who were responsive to first-line chemotherapy
        FPA-144
        Gastric Cancer & Gastroesophageal Cancer
        Evaluation of I/III randomized controlled trial of FPA144 combined with FOLFOX6 in the treatment of advanced gastric cancer
        ZL-2301 (Brivanib)
        Hepatocellular Carcinoma
        The efficacy, safety and pharmacokinetics of ZL-2301 in advanced liver cancer
        For more information about the above trials, please visit http://www.chinadrugtrials.org.cn/
        万彩吧